Pfizer Japan Logs 2.6% Growth in FY2018, No Job Cut Planned: Chief

Pfizer Japan President Akihisa Harada Pfizer Japan saw its sales rise 2.6% year on year in FY2018 through November last year as bullish performances by Ibrance (palbociclib) and other new products more than offset a 6% drug price cut it...read more